ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1204
-
Likes:
7
-
Views:
1204
-
Likes:
7
-
Up Next -
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
-
12m 4sPart 1 | Session 3 Late-Breaker Discussion: Insights from the STEP-HFpEF Harriette Van Spall, Mikhail Kosiborod
-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF Harriette Van Spall, Tauben Averbuch
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT Nicolas Girerd
-
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Michael Kiernan
-
7m 19sPart 2 | Session 3 Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Finn Gustafsson
-
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i Muthiah Vaduganathan
-
2m 54sPart 2 | Session 5 Treatment Benefit Consistency of Remote Hemodynamic Monitoring in CHF: MONITOR-HF Subgroup Analysis Jasper J Brugts
-
4m 46sPart 2 | Session 6 Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF Stefan Anker
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.
FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or heart failure enrolled in the ongoing FINEARTS-HF and the completed FIDELIO-DKD and FIGARO-DKD trials.
Interview Questions:
- What is the importance of this analysis?
- What trials were included in the analysis?
- What is the study design of the FINE-HEART study?
- What are the baseline characteristics of the patients?
- What are the next steps?
Recorded onsite at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editor: Jordan Rance, Mirjam Boros
Video Specialist: Dan Brent
Interviewer: Jonathan McKenna
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
Comments